Primary Endpoint of Cardiovascular Safety Met for Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS)
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Only registered members have full access to PracticeUpdate content.